Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Aardvark Therapeutics, Inc. (AARD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.11-11.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AARD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient cash runway into late 2027 | The company aims to maintain a cash runway into late 2027. | Intact | cash reserves fall below 60 million | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Based on current operating plans, Aardvark believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund projected operations into late 2027.” “Second Quarter 2026 Financial Highlights • Cash Position: As of June 30, 2026, Aardvark had cash, cash equivalents and short-term investments of $73.9 million, compared to $91.2 million as of March 31, 2026.” |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
AARD is a speculative, loss-making clinical-stage business rather than an established earnings compounder. Its thesis is in a watch state: management has completed a review of exploratory trial data, but clinical efficacy remains unestablished.
The valuation signal says AARD is cheap versus peers, but the model has medium confidence and the valuation measure fell from 48.2 to 24.1. The snapshot does not specify what clinical or financial expectations the market assumes, so the expectations gap is unclear; low fragility flags do not resolve that uncertainty.
Near term, the next results and guidance matter, and the stated miss-risk estimate is 47%; recent performance is neutral but below its industry cohort. Management projects cash runway into late 2027, though cash declined from $91.2 million at the end of March to $73.9 million at the end of June. The August earnings beat is a positive data point, but revenue does not establish clinical progress.
The multi-year thesis hinges on whether further clinical evidence can establish efficacy and support a clear path forward. Near term, guidance cuts or continued weakening in jobs data could add pressure, while stronger results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, AARD remains a high-risk, early-stage thesis with a stated cash runway but no established clinical efficacy. The evidence is mixed, so progress in clinical understanding and cash preservation are central. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Assess unblinded clinical data from HERO and OLE trials | A supporting condition in Aardvark Therapeutics, Inc.'s published investment case. The stated target is Complete assessment by Q3 2026. | Under Pressure | Assessment is delayed beyond Q3 2026 | Trial terminated vs Q3 2026 target FDA lifted hold on 2026-10-22, but prior news on 2026-10-19 explicitly cited trial termination threatening the data assessment. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve regulatory uncertainties surrounding ARD-101 | A primary condition in Aardvark Therapeutics, Inc.'s published investment case. The stated target is Approval by mid-2027. | Improving | regulatory hold extends beyond mid-2027 | FDA hold lifted Oct 2026 vs mid-2027 target FDA lifted clinical hold on ARD-101 in Oct 2026, removing the main regulatory uncertainty that had pressured the thesis. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-3.26 → $-2.36 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-3.26 | $1,026,000 | 8 / 6 |
| 2026-07-25 | $-3.26 | $1,026,000 | 8 / 6 |
| 2026-07-26 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-07-27 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-07-28 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-07-29 | $-3.10 | $0 | 9 / 10 |
| 2026-07-30 | $-3.10 | $0 | 9 / 10 |
| 2026-07-31 | $-3.10 | $0 | 9 / 10 |
| 2026-08-01 | $-3.10 | $0 | 9 / 10 |
| 2026-08-02 | $-3.10 | $0 | 9 / 10 |
| 2026-08-03 | $-3.10 | $0 | 9 / 10 |
| 2026-08-04 | $-3.10 | $0 | 9 / 10 |
| 2026-08-05 | $-3.10 | $0 | 9 / 10 |
| 2026-08-06 | $-3.10 | $0 | 9 / 10 |
| 2026-08-07 | $-3.10 | $0 | 9 / 10 |
| 2026-08-08 | $-3.10 | $0 | 9 / 10 |
| 2026-08-09 | $-3.10 | $0 | 9 / 10 |
| 2026-08-10 | $-3.10 | $0 | 9 / 10 |
| 2026-08-11 | $-3.10 | $0 | 9 / 10 |
| 2026-08-12 | $-3.10 | $0 | 9 / 10 |
| 2026-08-13 | $-3.10 | $0 | 9 / 10 |
| 2026-08-14 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-15 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-16 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-17 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-18 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-19 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-20 | $-3.15 | $1,026,000 | 9 / 6 |
| 2026-08-21 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-22 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-23 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-24 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-25 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-26 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-27 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-28 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-29 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-30 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-08-31 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-01 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-02 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-03 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-04 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-05 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-06 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-07 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-08 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-09 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-10 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-11 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-12 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-13 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-14 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-15 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-16 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-17 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-18 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-19 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-20 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-21 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-22 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-23 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-24 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-25 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-26 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-27 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-28 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-29 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-09-30 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-01 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-02 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-03 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-04 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-05 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-06 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-07 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-08 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-09 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-10 | $-2.56 | $1,026,000 | 9 / 6 |
| 2026-10-11 | $-2.43 | $1,026,000 | 9 / 6 |
| 2026-10-12 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-13 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-14 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-15 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-16 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-17 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-18 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-19 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-20 | $-2.43 | $1,026,000 | 8 / 5 |
| 2026-10-21 | $-2.40 | $1,026,000 | 9 / 5 |
| 2026-10-22 | $-2.40 | $1,026,000 | 9 / 5 |
| 2026-10-23 | $-2.40 | $1,026,000 | 9 / 5 |
| 2026-10-24 | $-2.41 | $1,026,000 | 8 / 5 |
| 2026-10-25 | $-2.41 | $1,026,000 | 8 / 5 |
| 2026-10-26 | $-2.41 | $1,026,000 | 8 / 5 |
| 2026-10-27 | $-2.41 | $1,026,000 | 8 / 5 |
| 2026-10-28 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-10-29 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-10-30 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-10-31 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-11-01 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-11-02 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-11-03 | $-2.36 | $1,026,000 | 9 / 6 |
| 2026-11-04 | $-2.36 | $1,026,000 | 9 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 4 Hold · 2 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 0 cuts · 0 unchanged · 3 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.